Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted allogeneic stem cell transplantation in patients with an unrelated donor.

1. Age > 18 years;

2. Patients with AML, myelodysplasia , ALL, CML in accelerated phase or blastic transformation, CLL, MM or (non) Hodgkin lymphoma, who underwent an allo-SCT with an unrelated donor who is matched for HLA-A, B, C, DR and DQ;

3. Life expectation of > 3 months;

4. WHO performance status of 0, 1 or 2;

5. Written informed consent according to the rules and regulations of the Leiden University Medical Center.

1. Use of systemic immunosuppressive treatment (due to GVHD);

2. Acute GVHD of the skin > grade 2 or progressive acute GVHD;

3. Progressive disease needing cytoreductive treatment;

4. Any concomitant disease preventing the safe administration of donor lymphocytes;

5. Severe psychological disturbances;

6. Severely limited life expectation due to diseases other than the malignancy;

7. Very high risk disease preceding allo-SCT for which already unselected DLI is planned to be given 3 months after allo-SCT.